Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Martí Carvajal, Arturo J ^a   Solà, Ivan ^b  

^a Iberoamerican Cochrane Network   (Venezuela)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTIFIBRINOLYTIC AGENT AMINO ACID; UNCLASSIFIED DRUG; AMINO ACID;

ACUTE LIVER DISEASE; ADVERSE OUTCOME; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; ACUTE DISEASE; BLOOD COAGULATION DISORDERS; CHRONIC DISEASE; COMPLICATION; GASTROINTESTINAL HEMORRHAGE;

ACUTE DISEASE; AMINO ACIDS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION DISORDERS; CHRONIC DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIVER DISEASES;

EID: 84957792135     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006007.pub4     Document Type: Review

References (81)

1. Colle I, Wilmer A, Le Moine O, Debruyne R, Delwaide J, Dhondt E, et al. Upper gastrointestinal tract bleeding management: Belgian guidelines for adults and children. Acta Gastro-Enterologica Belgica 2011; Vol. 74, issue 1:45-66.
2. Agarwal S, Joyner KA Jr, Swaim MW. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease. American Journal of Gastroenterology 2000;95(11):3218-24.
3. Alderson P. Absence of evidence is not evidence of absence. BMJ (Clinical Research Ed.) 2004;328:476-7.
4. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Seminars in Liver Disease 2002;22:83-96.
5. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
6. Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Experimental Biology and Medicine 2012;237(1):1-9.
7. Bennani-Baiti N, Daw HA. Primary hyperfibrinolysis in liver disease: a critical review. Clinical Advances in Hematology & Oncology 2011;9(3):250-2.
8. Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
9. Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [PUBMED: 18824466]
10. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al. How to formulate research recommendations. BMJ (Clinical Research Ed.) 2006;333(7572):804-6.
11. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. British Journal of Haematology 2005;129:307-21.
12. Chalmers I. Well informed uncertainties about the effects of treatments. BMJ (Clinical Research Ed.) 2004;328:475-6.
13. Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical Research Ed.) 2013;346:e7586.
14. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200-7.
15. Chiu J, Ketchum LH, Reid TJ. Transfusion-sparing hemostatic agents. Current Opinion in Hematology 2002;9:544-50.
16. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38:230-7.
17. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thrombosis Research 2008;121:675-80.
19. Frank L, Basch E, Selby JV. The PCORI perspective on patient-centered outcomes research. JAMA 2014;312(15):1513-4.
20. Gluud C, Nikolova D, Klingenberg SL. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2015, Issue 3. Art. No.: LIVER.
21. Gunawan B, Runyon B. The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis. Alimentary Pharmacology & Therapeutics 2006;23:115-20.
22. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology 2011;64(4):380-2.
23. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
24. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology 2011;64(4):395-400.
25. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-15.
26. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology 2011;64(12):1277-82.
27. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology 2011;64(12):1283-93.
28. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology 2011;64(12):1294-302.
29. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology 2011;64(12):1303-10.
30. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology 2011;64(12):1311-6.
31. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology 2013; Vol. 66, issue 2:158-72.
32. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines 11 - making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology 2013; Vol. 66, issue 2:151-7.
33. Hedner U. General haemostatic agents - fact or fiction?. Pathophysiology of Haemostasis and Thrombosis 2002;32 Suppl 1:33-6.
34. Henry DA, O'Connell DL. Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ (Clinical Research Ed.) 1989;298(6681):1142-8.
35. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ (Clinical Research Ed.) 2003;327(7414):557-60.
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
38. Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. American Journal of Gastroenterology 2001;96:1581-6.
39. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, Pennsylvania: Barnett International/PAREXEL, 1997.
40. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141:781-8.
41. Ioannidis JP. The art of getting it wrong. Research Synthesis Methods 2010;1(3-4):169-84.
42. Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials. BMC Medical Research Methodology 2014;14:34.
43. Kang LI, Mars WM. Fibrinolytic factors in liver fibrosis. Current Pharmaceutical Biotechnology 2011;12(9):1441-6.
44. Kavanagh C, Shaw S, Webster CR. Coagulation in hepatobiliary disease. Journal of Veterinary Emergency and Critical Care 2011;21(6):589-604.
45. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
46. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
47. Mannucci PM. Hemostatic drugs. New England Journal of Medicine 1998;339(4):245-53.
48. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012;72(5):585-617.
49. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352(9128):609-13.
50. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical Research Ed.) 2010;340:c869.
51. Moreno Abadía V, Bermúdez García JM, Maldonado Martín A, Rico Irles J. The incidence of consumption coagulopathy in liver cirrhosis. Anales de Medicina Interna 1989;6:466-71.
52. Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G, et al. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology 2000;31:349-57.
53. Piscaglia F, Donati G, Giannini R, Bolondi L. Liver cirrhosis, ascites, and hyperfibrinolysis. American Journal of Gastroenterology 2001;96:3222.
54. Pluta A, Gutkowski K, Hartleb M. Coagulopathy in liver diseases. Advances in Medical Sciences 2010;55(1):16-21.
55. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
56. Roberts LN, Patel RK, Arya R. Haemostasis and thrombosis in liver disease. British Journal of Haematology 2010;148(4):507-21.
57. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
58. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
59. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
60. Selby JV. The patient-centered outcomes research institute: a 2013 agenda for "research done differently". Population Health Management 2013;16(2):69-70.
61. Selby JV. Patient-Centered Outcomes Research Institute seeks to find out what works best by involving 'end-users' from the beginning. Journal of Comparative Effectiveness Research 2014; Vol. 3, issue 2:125-9.
62. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clinical Research Ed.) 2011;343:d4002.
63. Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?. International Journal of Epidemiology 2009;38(1):276-86.
64. Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
65. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual for trial sequential analysis (TSA), 2011. ctu.dk/tsa/files/tsa_manual.pdf (accessed 26 March 2015).
66. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. New England Journal of Medicine 2011;365(2):147-56.
67. Copenhagen Trial Unit. TSA - trial sequential analysis. 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
68. Téllez-Avila FI, Chávez-Tapia NC, Torre-Delgadillo A. Coagulation disorders in cirrhosis. Revista de Investigación Clínica 2007;59:153-60.
69. van der Werf J, Porte RJ, Lisman T. Hemostasis in patients with liver disease. Acta Gastro-Enterologica Belgica 2009;72(4):433-40.
70. van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Practice & Research. Clinical Gastroenterology 2008;22:209-24.
71. Van Thiel DH, George M, Mindikoglu AL, Baluch MH, Dhillon S. Coagulation and fibrinolysis in individuals with advanced liver disease [Geç dönem karaci∂er hastalýklarýnda koagulasyon ve fibrinolizis]. Turkish Journal of Gastroenterology 2004;15:67-72.
72. Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al. Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis. Hepatology 1992;15:672-6.
73. Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, et al. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis. Hepatology 1993;17:78-83.
74. Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK. Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?. Journal of Hepatology 2011;55(6):1415-27.
75. Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
76. Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random-effects model meta-analyses. BMC Medical Research Methodology 2009;9:86.
77. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601-5.
78. Universidad de Carabobo. Zavala D, Martí A, Peña-Martí G, Comunián G. Sheet to enter data for performing a Cochrane review. Valencia, Venezuela: Universidad de Carabobo, 2006.
79. Marti-Carvajal AJ, Pérez-Requejo JL. Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD006007]
80. Martí-Carvajal AJ, Solà I, Nicita G. Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006007.pub2]
81. Martí-Carvajal AJ, Solà I, Martí-Carvajal PI. Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD006007.pub3]